L-鸟氨酸-L-天冬氨酸在显性肝性脑病发作中的疗效
在印度两家三级医疗中心开展的前瞻性、双盲、随机、安慰剂对照试验中,193例肝硬化显性肝性脑病发作患者被随机分配接受静脉L-鸟氨酸-L-天冬氨酸(LOLA)30 g/日(n=98)或安慰剂(n=95)治疗5天,两组均接受乳果糖和头孢曲松标准治疗。结果显示LOLA组第1-4天肝性脑病分级显著低于安慰剂组(第5天无显著差异),恢复时间更短、第5天静脉血氨更低、住院时间更短,白细胞介素无显著差异。
要点
- LOLA组第1-4天肝性脑病分级显著低于安慰剂组,第5天无显著差异。
- LOLA组平均恢复时间1.92±0.93天,安慰剂组2.50±1.03天,P=0.002。
- LOLA组第5天静脉血氨和住院时间显著低于安慰剂组,白细胞介素无显著差异。
核心结论
- 在显性肝性脑病发作患者中,静脉LOLA作为乳果糖和头孢曲松的附加治疗,可显著改善第1-4天肝性脑病分级(第5天无显著差异),并降低静脉血氨、缩短恢复时间和住院时间。
研究设计与样本
- 前瞻性、双盲、随机、安慰剂对照试验,在印度两家三级医疗中心开展。
- 筛查370例肝硬化显性肝性脑病发作患者,排除后随机193例(52.16%)。
- LOLA组n=98,安慰剂组n=95,静脉输注30 g/日,共5天。
- 两组均接受标准治疗(包括乳果糖和头孢曲松)。
- 中央随机化,所有研究人员对治疗分配设盲。
主要发现
- LOLA组第1-4天肝性脑病分级显著低于安慰剂组,第5天无显著差异。
- 平均恢复时间LOLA组1.92±0.93天 vs 安慰剂组2.50±1.03天,P=0.002,95%CI -0.852至-0.202。
- LOLA组第5天静脉血氨和住院时间显著低于安慰剂组。
- 两组间白细胞介素无显著差异。
关键数值与推荐
- 主要结局为治疗第5天精神状态分级。
- 第0-5天每日检测空腹静脉血氨。
- 第0天和第5天检测血清肿瘤坏死因子-α、白细胞介素、血常规及肝肾功能。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
High-quality data on the efficacy of L-ornithine L-aspartate (LOLA) in patients with cirrhosis and bouts of overt hepatic encephalopathy (OHE) are missing. We evaluated the efficacy of intravenous LOLA in the reversal of bouts of OHE in patients with cirrhosis. In this prospective, double-blind, randomized, placebo-controlled trial conducted at two tertiary care institutes in India, 370 patients with cirrhosis and bouts of OHE were screened. After exclusion, 193 (52.16%) patients were randomized to receive either intravenous infusions of LOLA (n = 98), 30 g daily, or placebo (n = 95) for 5 days. Standard of care treatment (including lactulose and ceftriaxone) was given in both groups. Randomization was done centrally (http://www.sealedenvelope.com/). All study personnel were blinded to the treatment assignment. Fasting venous ammonia levels were estimated daily from 0 to 5 days. Serum tumor necrosis factor-alpha, interleukins, hemogram, and liver and renal function tests were performed at days 0 and 5. Primary outcome was mental state grade at day 5 of treatment. The grade of OHE was significantly lower in the LOLA group (compared to placebo) on days 1-4 but not on day 5. The mean time taken for recovery was lower in the LOLA group compared to the placebo group (1.92 ± 0.93 versus 2.50 ± 1.03 days, P = 0.002; 95% confidence interval -0.852 to -0.202). Venous ammonia at day 5 and length of hospital stay were significantly lower in the LOLA group. No significant difference in interleukins was seen between the groups. Conclusion: In patients with bouts of OHE, intravenous LOLA (as an add-on therapy to lactulose and ceftriaxone) significantly improves the grade of OHE over days 1-4, but not on day 5, and decreases venous ammonia, time of recovery, and length of hospital stay. (Hepatology 2018;67:700-710).
引用
- Sidhu SS, Sharma BC, Goyal O, et al. L-ornithine L-aspartate in bouts of overt hepatic encephalopathy. Hepatology. 2017. PMID: 28749571. doi:10.1002/hep.29410
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。